scholarly journals Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Pablo Florenzano ◽  
Francisco J. Guarda ◽  
Rodrigo Jaimovich ◽  
Nicolás Droppelmann ◽  
Hernán González ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Salivary Gland ◽  
Adverse Effects ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Dry Mouth ◽  
Low Doses ◽  
Periorbital Edema ◽  
Risk Patients ◽  
Taste Disorders

Context. Radioiodine (RAI) administration has adverse effects in patients treated for thyroid cancer (DTC), but there is scarce information regarding their intensity and duration.Objective. To evaluate frequency and intensity of early and late RAI-related symptoms in patients with DTC.Design. Observational prospective study.Patients. DTC patients who underwent thyroidectomy, with or without RAI.Measurements. Patients answered 2 surveys: (1) from 0 to 6 months and (2) between 6 and 18 months after initial treatment.Results. 110 patients answered the first survey and 61 both. Nearly 80 percent received RAI. Among early symptoms, periorbital edema, excessive tearing, salivary gland disturbances, dry mouth, taste disorders, and nausea were more frequent and intense among RAI patients. Regarding late symptoms, periorbital edema, salivary gland pain and swelling, and dry mouth were more frequent and intense in RAI patients. Frequency and intensity of adverse effects were not different between low and high RAI doses (50 versus ≥100 mCi).Conclusion. RAI-related symptoms are frequent and usually persist after 6 months of administration, even when low doses are given. This finding must be considered when deciding RAI administration, especially in low risk patients, among whom RAI benefit is controversial.

scholarly journals Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical trial

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Umesh Jayarajah ◽  
Mahilal Wijekoon ◽  
Sanjeewa A. Seneviratne
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Thyroid Cancer ◽  
Adverse Effects ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Oral Prednisolone ◽  
Single Centre ◽  
Double Blinded

Abstract Background Radioactive iodine (RAI) therapy is the standard adjuvant treatment for differentiated thyroid cancer (i.e. papillary and follicular). RAI is associated with troublesome early, intermediate and late adverse effects. Although glucocorticoids are used for the management of these adverse effects, there is little evidence regarding the effectiveness of prophylactic glucocorticoids to prevent these complications. This trial will evaluate the efficacy of a short course of prophylactic glucocorticoids in the prevention of adverse effects of RAI treatment in patients with differentiated thyroid cancer. Methods A phase II/III, single-centre, randomized, double-blinded, placebo-controlled, parallel-arm clinical trial will be conducted. Patients with differentiated thyroid cancer who are referred to RAI therapy at the National Cancer Institute, Sri Lanka, will be randomized into two arms consisting of 200 patients each. The experimental group will receive prophylactic oral prednisolone 0.5 mg/kg and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral prednisolone 0.5 mg/kg and omeprazole 20 mg daily for 3 days. The control group will receive oral placebo and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral placebo and omeprazole 20 mg daily for 3 days. Clinically significant adverse effects assessed as related to RAI as well as prednisolone therapy and the quality of life parameters will be compared between the two groups. Discussion If proven beneficial, this intervention can be incorporated into the standard practice to reduce early and intermediate adverse effects of RAI for thyroid cancer with a potential improvement of quality of life. Trial registration Sri Lanka Clinical Trials Registry SLCTR/2020/009. Registered prospectively on 23 February 2020. Items of the WHO Trial Registration Data Set are provided in the supplementary file.

scholarly journals A Randomized Controlled Trial for the Effectiveness of Aromatherapy in Decreasing Salivary Gland Damage following Radioactive Iodine Therapy for Differentiated Thyroid Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Michihiro Nakayama ◽  
Atsutaka Okizaki ◽  
Koji Takahashi
Keyword(s):  
Thyroid Cancer ◽  
Salivary Gland ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Control Group ◽  
Parotid Glands ◽  
Before And After ◽  
Group A ◽  
Gland Function ◽  
Group B

Objective. The aim of this study was to investigate effects of aromatherapy in decreasing salivary gland damage for patients undergoing radioactive iodine (RAI) therapy with differentiated thyroid cancer (DTC). Materials and Methods. The subjects were 71 patients with DTC. They were divided into aromatherapy group (group A, n=35) and a control group (group B, n=36). We blended 1.0 mL of lemon and 0.5 mL of ginger essential oils. The patients in the inhalation aromatherapy group inhaled this blend oil and those in the control group inhaled distilled water as placebo for 10 min during admission. We statistically compared salivary gland function before and after treatment between groups A and B. Results. In comparison with group B, the rate of change of the accumulation rate was significantly higher in the parotid glands and submandibular glands of group A (P<0.05). In comparison with group B, a significant increase in rate of secretion change before and after treatment was noted in the bilateral parotid glands in group A (P<0.05). Conclusion. Because an amelioration of salivary gland function was observed in the present study, our results suggest the efficacy of aromatherapy in the prevention of treatment-related salivary gland disorder. This trial is registered with UMIN Clinical Trial Registry: UMIN000013968.

scholarly journals Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single centre, phase II/III, randomized, double blinded, placebo controlled clinical trial

2020 ◽  
Author(s):  
Umesh Jayarajah ◽  
Mahilal Wijekoon ◽  
Sanjeewa Seneviratne
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Thyroid Cancer ◽  
Adverse Effects ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Oral Prednisolone ◽  
Single Centre ◽  
Double Blinded

Abstract BackgroundRadioactive iodine (RAI) therapy is the standard adjuvant treatment for differentiated thyroid cancer (i.e. papillary and follicular). RAI is associated with troublesome early, intermediate and late adverse effects. Although glucocorticoids are used for the management of these adverse effects, there is little evidence regarding the effectiveness of prophylactic glucocorticoids to prevent these complications. This trial will evaluate the efficacy of a short course of prophylactic glucocorticoids in the prevention of adverse effects of RAI treatment in patients with differentiated thyroid cancer.MethodsA phase II/III, single centre, randomized, double blinded, placebo controlled, parallel arm clinical trial will be conducted. Patients with differentiated thyroid cancer who are referred to RAI therapy at the National Cancer Institute, Sri Lanka will be randomised into two arms consisting of 200 patients each. The experimental group will receive prophylactic oral prednisolone 0.5mg/kg and omeprazole 20mg single dose 6 hours before RAI therapy followed by oral prednisolone 0.5mg/kg and omeprazole 20mg daily for 3 days. The control group will receive oral placebo and omeprazole 20mg single dose 6 hours before RAI therapy followed by oral placebo and omeprazole 20mg daily for 3 days. Clinically significant adverse effects assessed as related to RAI as well as prednisolone therapy and the quality of life parameters will be compared between the two groups.DiscussionIf proven beneficial, this intervention can be incorporated into the standard practice to reduce early and intermediate adverse effects of RAI for thyroid cancer with a potential improvement of quality of life. Trial registrationRegistration ID: Sri Lanka Clinical Trials Registry: SLCTR/2020/009 Registered prospectively on 23 February 2020. Url: https://slctr.lk/trials/slctr-2020-009

Does the radioactive iodine dose affect smell, taste sensation and nose function?

2021 ◽  
Vol 135 (1) ◽  
pp. 50-56
Author(s):  
B Tutar ◽  
T Özülker ◽  
G Berkiten ◽  
S Karaketir ◽  
M E Ekincioğlu ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Adverse Effects ◽  
Dose Group ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
High Dose ◽  
Test Results ◽  
Radioactive Iodine Therapy ◽  
Significant Difference ◽  
Iodine Dose

AbstractObjectiveTo detect whether the adverse effects of post-operative radioactive iodine therapy following differentiated thyroid cancer on smell, taste and nasal functions were associated with radioactive iodine dose.MethodsFifty-one patients who had undergone total thyroidectomy because of differentiated thyroid cancer were divided into two groups depending on the post-operative radioactive iodine therapy dose: low dose group (50 mCi; 21 patients) and high dose group (100–150 mCi; 30 patients). The Sniffin’ Sticks smell test, the Taste Strips test and the 22-item Sino-Nasal Outcome Test were performed on all patients one week before therapy, and at two months and one year following therapy.ResultsStatistically significant differences were detected in the Sniffin’ Sticks test results, total odour scores, total taste scores and Sino-Nasal Outcome Test results between the assessment time points. There was no statistically significant difference between the low and high dose groups in terms of odour, taste or Sino-Nasal Outcome Test scores either before or after therapy.ConclusionRadioactive iodine therapy has some short- and long-term adverse effects on nasal functions and taste and odour sensations, which affect quality of life. These effects are not dose-dependent.

scholarly journals Our experience with low doses of radioactive iodine (30 mCi) in patients with differentiated thyroid cancer

2016 ◽  
Author(s):  
Inmaculada Prior-Sanchez ◽  
Jimenez Concepcion Munoz ◽  
Moreno Paloma Moreno ◽  
Roman Angel Rebollo ◽  
Martin Ana Barrera ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Low Doses
Sign in / Sign up

Export Citation Format

Share Document